Fortschr Neurol Psychiatr 2010; 78(2): 81-89
DOI: 10.1055/s-0028-1109978
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Psychose und Sucht bei Jugendlichen und Jungerwachsenen
Teil 1: Prävalenz und Erklärungsmodelle

Dual Diagnosis Psychosis and Substance Use Disorders in Adolescents – Part 1K. Meister1 , M. Burlon1 , L. Rietschel1 , E. Gouzoulis-Mayfrank2 , T. Bock1 , M. Lambert1
  • 1Psychosen-Ersterkennungs- und Behandlungsprojekt (PEB), Klinik für Psychiatrie und Psychotherapie, Zentrum für Psychosoziale Medizin, Universitätskrankenhaus Hamburg-Eppendorf (Direktor: Prof. Dr. D. Naber)
  • 2LVR-Klinik Köln und Klinik für Psychiatrie und Psychotherapie, Universitätsklinik Köln (Direktor: Prof. Dr. J. Klosterkötter)
Further Information

Publication History

Publication Date:
09 February 2010 (online)

Zusammenfassung

Epidemiologische Studien bei schizophrenen Patienten zeigen ein Lebenszeitrisiko von 20 – 50 % für eine komorbide Suchtstörung. Bei Patienten mit einer ersten Episode liegt die Prävalenz für eine komorbide Suchterkrankung zwischen 25 – 75 %, vor allem Cannabisgebrauch. Diese schwierig zu behandelnde Patientengruppe hat meist einen schlechteren Verlauf als schizophrene Patienten, die keine komorbide Suchtstörung aufweisen. Trotz zahlreicher Erklärungsmodelle, wie der Selbstmedikationshypothese, allgemeinen oder bidirektionalen Faktorenmodellen oder genetischer Vulnerabilität, kann keines umfassend die hohe Suchtkomorbidität bei schizophrenen Patienten erklären, wobei dies wichtig wäre, um diese Gruppe besser behandeln zu können. Da die Gruppe der Doppeldiagnosepatienten sehr heterogen ist, ist es möglich, dass verschiedene Erklärungsmodelle die Komorbidität in verschiedenen Subgruppen erklären könnten. Der vorliegende erste Teil der Übersichtsarbeit „Doppeldiagnose Psychose und Sucht mit Schwerpunkt bei Jungerwachsenen” befasst sich mit der Prävalenz und Erklärungsmodellen. Der zweite Teil gibt dann eine Übersicht zu Verlauf und psychosozialen Behandlungsmöglichkeiten.

Abstract

Epidemiological studies suggest that 20 % to 50 % of patients with schizophrenia have a lifetime comorbid substance use disorder (SUD). In first-episode psychosis this prevalence is even higher and varies between 20 % and 75 % with cannabis being the most widely used illicit drug. These difficult to treat patients usually have a worse prognosis as compared with non-substance abusing schizophrenic patients. Despite multiple theories proposed such as the self medication hypothesis, common or bidirectional factor models or genetic vulnerability, there is no consensus on the aetiology of increased rates of substance use in people with psychosis which is important to treat these patients. The dually diagnosed population is a heterogeneous group and it is likely that different models may explain comorbidity in different subgroups. The present review part one gives an overview on prevalence and explanation models for dual diagnosis psychosis and substance use with focus in adolescent and young adult populations, the second part reviews the clinical course for both disorders and current psychosocial treatment options.

Literatur

  • 1 Buckley P F. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness.  Journal of Clinical Psychiatry. 2006;  67 5-9
  • 2 Drake R E. Dual diagnosis.  Psychiatry. 2007;  6 381-384
  • 3 Tiet Q Q, Mausbach B. Treatments for patients with dual diagnosis: a review.  Alcoholism: Clinical and Experimental Research. 2007;  31 513-536
  • 4 Weltgesundheitsorganisation .Internationale Klassifikation psychischer Störungen: ICD 10, Kapitel V (F); klinisch-diagnostische Leitlinien. Bern; Huber 2000 4th
  • 5 American Psychiatric Association .Diagnostisches und Statistisches Manual Psychischer Störungen – Textrevision- DSM-IV-TR. Göttingen; Hogrefe 2003
  • 6 Martin C S, Winters K C. Diagnosis and assessment of alcohol use disorders among adolescents.  Alcohol Health and Research World. 1998;  22 95-105
  • 7 Chambers R A, Krystal J H, Self D W. A neurobiological basis for substance abuse comorbidity in schizophrenia.  Biological Psychiatry. 2001;  50 71-83
  • 8 Lambert M, Conus P, Lubman D I. et al . The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis.  Acta Psychiatrica Scandinavica. 2005;  112 141-148
  • 9 Hickman M, Vickerman P, Macleod J. et al . Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales.  Addiction. 2007;  102 597-606
  • 10 Larsen T K, Melle I, Auestad B. et al . Substance abuse in first-episode non-affective psychosis.  Schizophrenia Research. 2006;  88 55-62
  • 11 Ajdacic-Gross V, Lauber C, Warnke I. et al . Changing incidence of psychotic disorders among the young in Zurich.  Schizophrenia Research. 2007;  95 9-18
  • 12 Verdoux H, Tournier M, Cougnard A. Impact of substance use on the onset and course of early psychosis.  Schizophrenia Research. 2005;  79 69-75
  • 13 Rehm J, Room R, Brink W. et al . Problematic drug use and drug use disorders in EU countries and Norway: an overview of the epidemiology.  European Neuropsychopharmacology. 2005;  15 389-397
  • 14 Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course.  American Journal on Addictions. 2006;  15 345 s-355
  • 15 Pfeiffer-Gerschel T, Kipke I, Lang P. et al .Bericht 2008 des nationalen REITOX-Knotenpunkts an die EBDD. Deutschland: Neue Entwicklungen, Trends und Hintergrundinformationen zu Schwerpunktthemen. Drogensituation 2007 / 2008. München; DBDD 2008
  • 16 Europäische Beobachtungsstelle für Drogen und Drogensucht (EBDD) .Jahresbericht 2008: Stand der Drogenproblematik in Europa. Luxemburg; Amt für amtliche Veröffentlichungen der Europäischen Gemeinschaften 2008: 1-111
  • 17 Kraus L, Augustin R, Orth B. Illegale Drogen, Einstiegsalter und Trends. Ergebnisse des Epidemiologischen Suchtsurvey 2003.  Sucht. 2005;  51 19-28
  • 18 Perkonigg A, Lieb R, Höfler M. et al . Patterns of cannabis use, abuse and dependence over time: incidence, progression and stability in a sample of 1228 adolescents.  Addiction. 1999;  94 1663-1678
  • 19 Sydow von K, Lieb R, Pfister H. et al . The natural course of cannabis use, abuse and dependence over 4 years: a longitudinal community study of adolescents and young adults.  Drug and Alcohol Dependence. 2001;  64 347-361
  • 20 Töppich J. Cannabiskonsum von Jugendlichen. In, Jugendkult Cannabis – Risiken und Hilfen. Berlin; Die Drogenbeauftragte der Bundesregierung 2005: 15-19
  • 21 Bonnet U, Harries-Hedder K, Leweke F M. et al . AWMF-Leitlinie: Cannabis-bezogene Störungen.  Fortschr Neurol Psychiatr. 2004;  72 318-329
  • 22 Thomasius R, Stolle M. Diagnostik und Behandlung psychischer Störungen durch Cannabiskonsum.  Psychiatrie und Psychotherapie up2date 2. 2008;  2 225-239
  • 23 Sonntag D, Bauer C, Hellwich A K. Deutsche Suchthilfestatistik 2005 für ambulante Suchteinrichtungen.  Sucht. 2006;  52 7-43
  • 24 Bundeszentrale für gesundheitliche Aufklärung (BZgA) .Cannabiskonsum der Jugendlichen und jungen Erwachsenen in Deutschland. Ergebnisse der Repräsentativbefragung der Bundeszentrale für gesundheitliche Aufklärung. Köln; BZgA 2007
  • 25 Die Drogenbeauftragte der Bundesregierung .Drogen- und Suchtbericht Mai 2008. Berlin; 2008
  • 26 Bundeszentrale für gesundheitliche Aufklärung (BZgA) .Alkoholkonsum der Jugendlichen in Deutschland 2004 – 2007. Ergebnisse der Repräsentativbefragung der Bundeszentrale für gesundheitliche Aufklärung. Köln; BZgA 2007
  • 27 Rabinowitz J, Bromet E J, Lavelle J. et al . Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients.  Psychological Medicine. 1998;  28 1411-1419
  • 28 Green B, Young R, Kavanagh D J. Cannabis use and misuse prevalence among people with psychosis.  British Journal of Psychiatry. 2005;  187 306-313
  • 29 Blanchard J J, Brown S A, Horan W P. et al . Substance use disorders in schizophrenia: review, integration, and a proposed model.  Clinical Psychology Review. 2000;  20 207-234
  • 30 Kraemer H C, Wilson K A, Hayward C. Lifetime prevalence and pseudocomorbidity in psychiatric research.  Archives of General Psychiatry. 2006;  63 604-608
  • 31 Regier D A, Farmer M E, Rae D S. et al . Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.  Journal of the American Medical Association. 1990;  264 2511-2518
  • 32 Jacobsen L K, Southwick S M, Kosten T R. Substance use disorders in patients with posttraumatic stress disorder: a review of the literature.  American Journal of Psychiatry. 2001;  158 1184-1190
  • 33 Kalbag A S, Levin F R. Adult ADHD and substance abuse: diagnostic and treatment issues.  Substance Use & Misuse. 2005;  40 1955-1958
  • 34 Duke P J, Pantelis C, McPhillips M A. Comorbid non-alcohol substance misuse among people with schizophrenia.  British Journal of Psychiatry. 2001;  179 509-513
  • 35 Lammertink M, Löhrer F, Kaiser R. Differences in substance abuse patterns: multiple drug abuse alone versus schizophrenia with multiple drug abuse.  Acta Psychiatrica Scandinavica. 2001;  104 361-366
  • 36 Linszen D H, Dingemans P M, Lenior M E. Cannabis use and the course of recent onset schizophrenic disorders.  Archives of General Psychiatry. 1994;  51 273-279
  • 37 Wade D, Harrigan S, Edwards J. et al . Course of substance misuse and daily tobacco use in first-episode psychosis.  Schizophrenia Research. 2006;  81 145-150
  • 38 Kavanagh D J, Waghorn G, Jenner L. et al . Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample.  Schizophrenia Research. 2004;  66 115-124
  • 39 Wobrock T, Pajonk F G, D’Amelio R. et al . Schizophrenie und Sucht.  psychoneuro. 2005;  31 433-440
  • 40 Gouzoulis-Mayfrank E. Doppeldiagnose Psychose und Sucht – Grundlagen und Therapie.  Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie. 2008;  36 245-253
  • 41 Gouzoulis-Mayfrank E. Komorbidität Psychose und Sucht: Grundlagen und Praxis. Steinkopff Verlag 2007
  • 42 Tiet Q Q, Finney J W, Moos R H. Screening psychiatric patients for illicit drug use disorders and problems.  Clinical Psychology Review. 2008;  28 578-591
  • 43 Drake R E, Wallach M A, McGovern M P. Future directions in preventing relapse to substance abuse among clients with severe mental illnesses.  Psychiatric Services. 2005;  56 1297-1302
  • 44 Cutler D L, Bevilacqua J, McFarland B H. Four decades of community mental health: a symphony in four movements.  Community Mental Health Journal. 2003;  39 381-398
  • 45 Drake R E, Green A I, Mueser K T. The history of community mental health treatment and rehabilitation for persons with severe mental illness.  Community Mental Health Journal. 2003;  39 427-440
  • 46 Mueser K T, Drake R E, Wallach M A. Dual diagnosis: a review of etiological theories.  Addictive Behaviors. 1998;  23 717-734
  • 47 Gregg D, Barrowclough C, Haddock G. Reasons for increased substance use in psychosis.  Clinical Psychology Review. 2007;  27 494-510
  • 48 Khantzian E J. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications.  Harvard Review of Psychiatry. 1997;  4 231-244
  • 49 Schneier F R, Siris S G. A review of psychoactive substance use and abuse in schizophrenia.  Journal of Nervous and Mental Disease. 1987;  175 641-652
  • 50 Dixon L, Haas G H, Weiden P J. et al . Drug abuse in schizophrenic patients: clinical correlates and reasons for use.  American Journal of Psychiatry. 1991;  148 224-230
  • 51 Pencer A, Addington J. Reasons for using substances in adolescents with and without psychosis.  Early Intervention in Psychiatry. 2008;  2 42-44
  • 52 Addington J, Duchak V. Reasons for substance use in schizophrenia.  Acta Psychiatrica Scandinavica. 1997;  96 233-329
  • 53 Spencer C, Castle D, Michie P T. Motivations that maintain substance use among individuals with psychotic disorders.  Schizophrenia Bulletin. 2002;  28 233-247
  • 54 Cantwell R, Brewin J, Glazebrook C. et al . Prevalence of substance misuse in first-episode psychosis.  British Journal of Psychiatry. 1999;  174 150-153
  • 55 Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia.  Biological Psychiatry. 1996;  40 1155-1163
  • 56 Bersani G, Orlandi V, Kotzalidis G D. et al . Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes.  European Archives of Psychiatry and Clinical Neuroscience. 2002;  252 86-92
  • 57 Canton-Graae E, Nordstrom L G, McNeil T F. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden.  Schizophrenia Research. 2001;  48 69-82
  • 58 Barnett J H, Werners U, Secher S M. et al . Substance use in a population-based clinic sample of people with first-episode psychosis.  British Journal of Psychiatry. 2007;  190 515-520
  • 59 Drake R E, Wallach M A, Alverson H S. et al . Psychosocial aspects of substance abuse by clients with severe mental illness.  Journal of Nervous and Mental Disease. 2002;  190 100-106
  • 60 Drake R E, Mueser K T. Co-occuring alcohol use disorder and schizophrenia.  Alcohol Research and Health. 2002;  26 99-102
  • 61 Drake R E, Wallach M A. Moderate drinking among people with severe mental illness.  Hospital and Community Psychiatry. 1993;  44 780-782
  • 62 Swofford C D, Kasckow J W, Scheller-Gilkey G. Substance use: a powerful predictor of relapse in schizophrenia.  Schizophrenia Research. 1996;  20 145-151
  • 63 Gonzalez V M, Bradizza C M, Vincent P C. et al . Do individuals with a severe mental illness experience greater alcohol and drug-related problems? A test of the supersensitivity hypothesis.  Addictive Behaviors. 2007;  32 477-490
  • 64 Phillips P, Johnson S. How does drug and alcohol misuse develop among people with psychotic illness? A literature review.  Social Psychiatry and Psychiatric Epidemiology. 2001;  36 269-276
  • 65 O’Daly O G, Guillin O, Tsapakis E. et al . Schizophrenia and substance abuse comorbidity: a role for dopamine sensitization?.  Journal of Dual Diagnosis. 2005;  1 11-40
  • 66 Rounsaville B J. DSM-V research agenda: substance abuse/psychosis comorbidity.  Schizophrenia Bulletin. 2007;  33 947-952
  • 67 Thornicroft G, Meadows G, Politi P. Is „cannabis psychosis” a distinct category?.  European Psychiatry. 1992;  7 277-282
  • 68 Arendt M, Rosenberg R, Foldager L. et al . Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases.  British Journal of Psychiatry. 2005;  187 510-515
  • 69 Arendt M, Preben B M, Rosenberg R. et al . Familial predisposition for psychiatric disorder comparison of subjects treated for cannabis-induced psychosis and schizophrenia.  Archives of General Psychiatry. 2008;  65 1269-1274
  • 70 Boydell J, Dean K, Dutta R. et al . A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis.  Schizophrenia Research. 2007;  93 203-210
  • 71 Caton C L, Hasin D S, Shrout P E. et al . Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis.  British Journal of Psychiatry. 2007;  190 105-111
  • 72 Caton C L, Drake R E, Hasin D S. Differences between early phase primary psychotic disorders with concurrent substance use and substance-induced psychosis.  Archives of General Psychiatry. 2005;  62 137-145
  • 73 Leweke F M, Gerth C W, Klosterkotter J. Cannabis-associated psychosis: current status of research.  CNS Drugs. 2004;  18 895-910
  • 74 Fergusson D M, Poulton R, Smith P F. et al . Cannabis and psychosis.  British Medical Journal. 2006;  332 172-175
  • 75 Arseneault L, Cannon M, Witton J. et al . Causal association between cannabis and psychosis: examination of the evidence.  British Journal of Psychiatry. 2004;  184 110-117
  • 76 Henquet C, Murray R, Linszen D. et al . The environment and schizophrenia: the role of cannabis use.  Schizophrenia Bulletin. 2005;  31 608-612
  • 77 Henquet C, Di Forti M, Morrison P. et al . Gene-environment interplay between cannabis and psychosis.  Schizophrenia Bulletin. 2008;  34 1111-1121
  • 78 Andreasson S, Allebeck P, Engstrom A. Cannabis and schizophrenia. A longitudinal study of swedish conscripts.  Lancet. 1987;  2 1483-1486
  • 79 Zammit S, Allebeck P, Andreasson S. et al . Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.  British Medical Journal. 2002;  325 1199
  • 80 Moore T, Zammit S, Lingford-Hughes A. et al . Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.  Lancet. 2007;  370 319-328
  • 81 Webb E, Ashton C H, Kelly P. et al . Alcohol and drug use in UK university students.  Lancet. 1996;  348 922-925
  • 82 Arseneault L, Cannon M, Poulton R. et al . Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.  British Medical Journal. 2002;  325 1212-1213
  • 83 Lieb R, Isensee B, v. Sydow K. et al . The Early Developmental Stages of Psychopathology Study (EDSP): a methodological update.  European Addiction Research. 2000;  6 170-182
  • 84 DeWitt D J, Adlaf E M, Offord D R. et al . Age at first alcohol use: a risk factor for the development of alcohol disorders.  American Journal of Psychiatry. 2000;  157 745-750
  • 85 Chen C Y, Brian M S, Anthony J C. Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000 – 2001.  Drug and Alcohol Dependence. 2005;  79 11-22
  • 86 Rabinowitz J, Levine S Z, Häfner H. A population based elaboration of the role of age of onset on the course of schizophrenia.  Schizophrenia Research. 2006;  88 96-101
  • 87 Nimwegen van L, Haan de L, Beveren van N. et al . Adolescence, schizophrenia and drug abuse: a window of vulnerability.  Acta Psychiatrica Scandinavica. 2005;  11 1-9
  • 88 Pistis M, Perra S, Pillolla G. et al . Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons.  Biological Psychiatry. 2004;  56 86-94
  • 89 Solowij N, Michie P T. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?.  Journal of Psychiatry and Neuroscience. 2007;  32 30-52
  • 90 Stefanis N C, Delespaul P, Henquet C. et al . Early adolescent cannabis exposure and positive and negative dimensions of psychosis.  Addiction. 2004;  99 1333-1341
  • 91 Konings M, Henquet C, Maharajh H D. et al . Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad.  Acta Psychiatrica Scandinavica. 2008;  118 209-213
  • 92 Barnes T, Mutsatsa S, Hutton S. et al . Comorbid substance use and age at onset of schizophrenia.  British Journal of Psychiatry. 2006;  188 237-242
  • 93 Veen N D, Selten P J, Tweel van der I. et al . Cannabis use and age at onset of schizophrenia.  American Journal of Psychiatry. 2004;  161 501-506
  • 94 Mastrigt van S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program.  Social Psychiatry and Psychiatric Epidemiology. 2004;  39 69-72
  • 95 Buhler B, Hambrecht M, Loffler W. et al . Precipitation and determination of the onset and course of schizophrenia by substance abuse – a retrospective and prospective study of 232 population-based first illness episodes.  Schizophrenia Research. 2002;  54 243-251
  • 96 Compton M T, Kelley M E, Ramsay C E. et al . Association of Pre-Onset Cannabis, Alcohol, and Tobacco Use With Age at Onset of Prodrome and Age at Onset of Psychosis in First-Episode Patients.  Am J Psychiatry. 2009;  166 1251-1257
  • 97 Semple D M, McIntosh A M, Lawrie S M. Cannabis as a risk factor for psychosis: systematic review.  Journal of Psychopharmacology. 2005;  19 187-194
  • 98 vanNimwegen L, Haan de L, Beveren van N. et al . Adolescence, schizophrenia and drug abuse: a window of vulnerability.  Acta Psychiatr Scand. 2005;  11 1-9
  • 99 Williams H J, Owen M J, O’Donovan M C. Is COMT a susceptibility gene for schizophrenia?.  Schizophrenia Bulletin. 2007;  33 635-641
  • 100 Collaborative Working Group on Clinical Trial Evaluations . Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders.  Journal of Clinical Psychiatry. 1998;  59 41-45
  • 101 Zammit S, Spurlock G, Williams H. et al . Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use.  British Journal of Psychiatry. 2007;  191 402-407
  • 102 Winkel van R, Hert de M, Vriendt de N. et al . No comfirmation of gene-environment interaction between COMT VAL158 MET and adolescent-onset cannabis use in large sample of patients with schizophrenia.  Schizophrenia Research. 2008;  98 78-79
  • 103 Kirkbride J, Fearon P, Morgan C. et al . Heterogenity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study.  Archives of General Psychiatry. 2006;  63 250-258
  • 104 Boydell J, Os O J, Caspi van A. et al . Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999.  Psychological Medicine. 2006;  36 1441-1446
  • 105 Os van J, Rutten B P, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions.  Schizophrenia Bulletin. 2008;  34 1066-1082
  • 106 Winkel van R, Stefanis N C, Myin-Germeys I. Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction.  Schizophrenia Bulletin. 2008;  34 1095-1105
  • 107 Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis.  Drug and Alcohol Dependence. 2003;  71 37-48
  • 108 Mueser K T, Crocker A G, Frisman L B. et al . Conduct disorder and antisocial personality disorder in persons with severe psychiatric and substance use disorders.  Schizophrenia Bulletin. 2006;  32 626-636
  • 109 Mueser K T, Yarnold P R, Rosenberg S D. Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups.  Schizophrenia Bulletin. 2000;  26 179-192
  • 110 Hides L, Dawe S, Kavanagh D J. et al . Psychotic symptom and cannabis relapse in recent-onset psychosis.  British Journal of Psychiatry. 2006;  189 137-143
  • 111 Ferdinand R F, Sondeijker F, Ende van der J. et al . Cannabis use predicts future psychotic symptoms, and vice versa.  Addiction. 2005;  100 612-618

PD Dr. Martin Lambert

Psychosen-Ersterkennungs- und Behandlungsprojekt (PEB)
Klinik für Psychiatrie und Psychotherapie, Zentrum für Psychosoziale Medizin
Universitätsklinikum Hamburg-Eppendorf

Martinistr. 52

20246 Hamburg

Email: lambert@uke.de

    >